The serum concentration of Diclofenac can be increased when it is combined with Amiodarone. The metabolism of Diclofenac can be decreased when combined with Etravirine. Diclofenac may increase the neuroexcitatory activities of Gatifloxacin. The risk or severity of adverse effects can be increased when Diclofenac is combined with ME-609. Diclofenac may increase the anticoagulant activities of Becaplermin. The metabolism of Diclofenac can be decreased when combined with Venlafaxine. Diclofenac may increase the anticoagulant activities of Phenindione. The risk or severity of adverse effects can be increased when Diclofenac is combined with Ulobetasol. The risk or severity of adverse effects can be increased when Diclofenac is combined with Risedronate. Diclofenac may decrease the antihypertensive activities of Metoprolol. Diclofenac may decrease the excretion rate of Plicamycin which could result in a higher serum level. The metabolism of Diclofenac can be decreased when combined with Nefazodone. The risk or severity of adverse effects can be increased when Diclofenac is combined with Ferulic acid. The risk or severity of adverse effects can be increased when Diclofenac is combined with Halcinonide. The risk or severity of bleeding can be increased when Betrixaban is combined with Diclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Indoprofen. The risk or severity of adverse effects can be increased when Diclofenac is combined with Mycophenolate mofetil. The serum concentration of Diclofenac can be increased when it is combined with Quazepam. Diclofenac may increase the anticoagulant activities of Apixaban. Sarilumab may increase the immunosuppressive activities of Diclofenac. The metabolism of Diclofenac can be decreased when combined with Pioglitazone. Diclofenac may increase the neuroexcitatory activities of Temafloxacin. Diclofenac may increase the anticoagulant activities of Gabexate. Diclofenac may increase the anticoagulant activities of Abciximab. The risk or severity of adverse effects can be increased when Trandolapril is combined with Diclofenac. The serum concentration of Vancomycin can be increased when it is combined with Diclofenac. The metabolism of Diclofenac can be decreased when combined with Lapatinib. Diclofenac may decrease the excretion rate of Geneticin which could result in a higher serum level. Diclofenac may increase the anticoagulant activities of Dalteparin. Diclofenac may decrease the antihypertensive activities of Carvedilol. The risk or severity of adverse effects can be increased when Diclofenac is combined with Felbinac. Diclofenac may increase the anticoagulant activities of Ardeparin. The metabolism of Diclofenac can be decreased when combined with Losartan. The serum concentration of Diclofenac can be increased when it is combined with Netupitant. Diclofenac may decrease the antihypertensive activities of Alprenolol. Diclofenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Diclofenac is combined with Haloperidol. The risk or severity of adverse effects can be increased when Diclofenac is combined with Prasterone sulfate. Diclofenac may decrease the antihypertensive activities of Betaxolol. The serum concentration of Afatinib can be increased when it is combined with Diclofenac. Diclofenac may decrease the antihypertensive activities of Hydralazine. Diclofenac may decrease the antihypertensive activities of Propranolol. The metabolism of Diclofenac can be decreased when combined with Telaprevir. The serum concentration of Diclofenac can be increased when it is combined with Nicardipine. The risk or severity of adverse effects can be increased when Diclofenac is combined with Anisodamine. The serum concentration of Diclofenac can be decreased when it is combined with Primidone. The risk or severity of adverse effects can be increased when Diclofenac is combined with Meclofenamic acid. The metabolism of Diclofenac can be decreased when combined with Modafinil. The metabolism of Diclofenac can be decreased when combined with Esomeprazole. The therapeutic efficacy of Iloprost can be decreased when used in combination with Diclofenac. Diclofenac may decrease the excretion rate of Streptozocin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Diclofenac is combined with Alclofenac. Diclofenac may decrease the antihypertensive activities of Carteolol. The serum concentration of Diclofenac can be increased when it is combined with Gemfibrozil. Diclofenac may decrease the excretion rate of Amrubicin which could result in a higher serum level. The serum concentration of Diclofenac can be increased when it is combined with Peginterferon alfa-2b. The serum concentration of Silodosin can be increased when it is combined with Diclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Prednicarbate. The risk or severity of adverse effects can be increased when Diclofenac is combined with Naproxen. The metabolism of Diclofenac can be increased when combined with Pentobarbital. Diclofenac may decrease the excretion rate of Metrizamide which could result in a higher serum level. The risk or severity of adverse effects can be increased when Olmesartan is combined with Diclofenac. The risk or severity of adverse effects can be increased when Tasosartan is combined with Diclofenac. Diclofenac may increase the nephrotoxic activities of Tacrolimus. The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diclofenac. The therapeutic efficacy of Unoprostone can be decreased when used in combination with Diclofenac. The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Diclofenac. The metabolism of Diclofenac can be decreased when combined with Thiotepa. The risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenac. Diclofenac may increase the neuroexcitatory activities of Prulifloxacin. The serum concentration of Vincristine can be increased when it is combined with Diclofenac. The metabolism of Diclofenac can be decreased when combined with Topiramate. Diclofenac may decrease the antihypertensive activities of Bucindolol. The metabolism of Diclofenac can be decreased when combined with Efavirenz. The risk or severity of adverse effects can be increased when Diclofenac is combined with Methylprednisolone. Diclofenac may decrease the excretion rate of Netilmicin which could result in a higher serum level. Diclofenac may increase the anticoagulant activities of Antithrombin III human. Diclofenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level. The therapeutic efficacy of Dinoprost can be decreased when used in combination with Diclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Antipyrine. Diclofenac may decrease the antihypertensive activities of Bopindolol. The risk or severity of adverse effects can be increased when Diclofenac is combined with Isoxicam. The risk or severity of adverse effects can be increased when Diclofenac is combined with Apremilast. The serum concentration of Diclofenac can be decreased when it is combined with Cyproterone acetate. The metabolism of Diclofenac can be decreased when combined with Theophylline. The metabolism of Diclofenac can be decreased when combined with Clemastine. The risk or severity of adverse effects can be increased when Diclofenac is combined with Zaltoprofen. The metabolism of Diclofenac can be decreased when combined with Rabeprazole. Diclofenac may decrease the antihypertensive activities of Labetalol. Diclofenac may decrease the antihypertensive activities of Befunolol. The risk or severity of adverse effects can be increased when Diclofenac is combined with Diflunisal. The metabolism of Diclofenac can be decreased when combined with Irbesartan. The risk or severity of adverse effects can be increased when Diclofenac is combined with Acemetacin. The serum concentration of Diclofenac can be decreased when it is combined with Mitotane. The metabolism of Diclofenac can be decreased when combined with Citalopram. Diclofenac may decrease the antihypertensive activities of Nebivolol. Diclofenac may decrease the excretion rate of Neomycin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Diclofenac is combined with Ketoprofen. The metabolism of Diclofenac can be decreased when combined with Isradipine. The serum concentration of Diclofenac can be increased when it is combined with Capecitabine. The metabolism of Diclofenac can be decreased when combined with Isoniazid. The metabolism of Diclofenac can be decreased when combined with Fosamprenavir. The serum concentration of Diclofenac can be increased when it is combined with Fosaprepitant. The metabolism of Diclofenac can be decreased when combined with Rosiglitazone. Diclofenac may increase the anticoagulant activities of Fondaparinux. Diclofenac may increase the anticoagulant activities of Fondaparinux sodium. The risk or severity of adverse effects can be increased when Diclofenac is combined with Atamestane. The risk or severity of adverse effects can be increased when Quinapril is combined with Diclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Tarenflurbil. The risk or severity of adverse effects can be increased when Diclofenac is combined with Diflorasone. Diclofenac may increase the anticoagulant activities of Danaparoid. The metabolism of Diclofenac can be decreased when combined with Lopinavir. The risk or severity of adverse effects can be increased when Diclofenac is combined with Magnesium salicylate. The risk or severity of adverse effects can be increased when Diclofenac is combined with Nepafenac. The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Diclofenac. The risk or severity of adverse effects can be increased when Diclofenac is combined with Higenamine. The serum concentration of Diclofenac can be decreased when it is combined with Enzalutamide. The risk or severity of adverse effects can be increased when Diclofenac is combined with Mometasone. The risk or severity of adverse effects can be increased when Temocapril is combined with Diclofenac. Diclofenac may decrease the antihypertensive activities of Penbutolol. The risk or severity of adverse effects can be increased when Diclofenac is combined with Loxoprofen. Diclofenac may increase the nephrotoxic activities of Cyclosporine. Diclofenac may decrease the antihypertensive activities of Bupranolol. The serum concentration of Diclofenac can be increased when it is combined with Tolbutamide. The serum concentration of Brentuximab vedotin can be increased when it is combined with Diclofenac. Diclofenac may increase the neuroexcitatory activities of Levofloxacin. Diclofenac may increase the anticoagulant activities of Ximelagatran. The metabolism of Diclofenac can be decreased when combined with Posaconazole. The risk or severity of adverse effects can be increased when Diclofenac is combined with Etidronic acid. The metabolism of Diclofenac can be increased when combined with Nevirapine.